Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autophagy

- PMLiVE

Novo Nordisk enters new research alliance for diabetes and cardiometabolic diseases

The collaboration will focus on advancing three programmes across the next three years

- PMLiVE

ICR study finds way to determine efficacy of experimental breast cancer drugs

The findings could speed up the development of targeted therapies for breast cancer

- PMLiVE

Medscape’s Virtual Patient Simulation Makes a Significant Impact on Real-World Treatment Selection for T2D

An analysis of data using Real-World Outcomes showed that a virtual patient simulation had a significant effect on real-world treatment selection for T2D. The paper, published in JMIR Medical Education,...

Medscape Education Global

- PMLiVE

New screening model shown to predict ten year breast cancer mortality risk

The risk-based screening model works to identify those at the highest risk of cancer

- PMLiVE

New blood test could one day be used to diagnose Parkinson’s disease

The discovery could potentially lead to the development of a definitive diagnostic test

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

- PMLiVE

Merck receives EC approval for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer

Medullary thyroid cancer only accounts for up to 2% of thyroid cancers in the US

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links